Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Might be a chance at upper 4's again tomorrow but I bet it pops soon again.
IMO
You and you alone hit the buy and sell button.... This is actually a huge opportunity to make money if you play your cards right. Stocks that move are a traders dream!
Do I think we will hit 7 again within a few weeks....YUP.
Amarantus to Present at Two Upcoming Investor Conferences
-Marcum Microcap Conference Presentation on May 28, 2015, at 2:30 p.m. EDT / 11:30 a.m. PDT-
-LD Micro Invitational Presentation and Webcast on June 2, 2015, at 1:30 p.m. EDT / 10:30 a.m. PDT-
Before this major step forward MANF was a wish, now it is on the path to becoming a reality.
No doubt there!...lol Wish everyone would use this as a platform for finding answers instead of bickering over who is right and wrong.
Working together to decipher each aspect of the company.
I don't fault anyone for asking questions!
Let's keep this civil all!!
We have a president who has no knowledge on how to be president...maybe that's the American way...fake it till you make it.
Why don't you send an email to the GC himself??
He might just answer.
Expecting answers while belittling is generally not conducive.
When combined with oligoclonal banding tests (OCB), sensitivity improved to 96% and specificity improved to 83%.
Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise(R) Diagnostic for Multiple Sclerosis
Download PDF
-MSPrecise blood diagnostic shows statistically significant sensitivity and specificity for classifying presentation of multiple sclerosis-
-Data supports further research into blood-based approach -
SAN FRANCISCO, May 11, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has reported preliminary data from the blood-based version of its MSPrecise® diagnostic, the Company's proprietary multiple sclerosis (MS) diagnostic test.
MSPrecise, a next-generation DNA sequencing (NGS) assay, measures DNA mutations found in rearranged immunoglobulin genes in immune cells (B cells) to identify patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation.
Results from the most recent MSPrecise validation study using cerebrospinal fluid (CSF) samples for MS, reported in January 2015, demonstrated an 86% sensitivity and 71% specificity in correctly identifying early-stage RRMS in subjects being evaluated for a demyelinating disease undergoing the current diagnostic standard of care (clinical evaluation, magnetic resonance imaging and oligoclonal banding tests), as adjudicated by an expert panel of physicians. When combined with oligoclonal banding tests (OCB), sensitivity improved to 96% and specificity improved to 83%.
Today, Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc., reported preliminary MSPrecise blood assay results from the same study (collected concurrently with CSF from the same patients). In the study, preliminary results indicate that the MSPrecise blood assay exhibited an 81% sensitivity and 89% specificity for identifying early-stage RRMS in subjects being evaluated for a demyelinating disease undergoing the current diagnostic standard of care. These results have not yet been combined with OCB and will require replication prior to moving into a CLIA validation study.
"These early findings are encouraging, and provide a pathway to further define and refine the MSPrecise blood assay," commented Colin Bier, Chief Development Officer of Amarantus Diagnostics. "Of particular importance, in this initial blood study, is the promising and positive analytical performance. There is such a high rate of misdiagnosis of MS, especially upon first clinical presentation of this chronic and extremely debilitating disease, that a blood test would be of great benefit to patients and physicians. We are preparing MSPrecise CSF for a CLIA-enabling validation study and, in parallel, will actively continue research and development of the MSPrecise blood assay."
"MSPrecise is potentially a groundbreaking advancement for the diagnosis of multiple sclerosis. Based on the CSF validation data, we anticipate moving into a CLIA validation that is currently in the planning stages," added Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. "The MSPrecise CSF assay, along with our LymPro Test® blood diagnostic for Alzheimer's disease, are the two of key assets in our diagnostics division. Together, MSPrecise and LymPro will allow Amarantus Diagnostics to very rapidly achieve critical mass as one of the premier neurodiagnostic testing companies in the world."
LymPro is currently available as a diagnostic assay for Investigational Use Only (IUO) in pharmaceutical therapeutic clinical development programs. Amarantus plans to advance MSPrecise and LymPro into CLIA validation studies in parallel later this year to prepare for the launch of MSPrecise and LymPro under the CLIA designation for marketing to the broader medical community in the United States.
About MSPrecise®
MSPrecise® is a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. MSPrecise utilizes next-generation sequencing to measure DNA mutations found in rearranged immunoglobulin genes in immune cells initially isolated from cerebrospinal fluid. MSPrecise would augment the current standard of care for the diagnosis of MS by providing a more accurate assessment of a patient's immune response to a challenge within the central nervous system. This novel method of measuring changes in adaptive human immunity may also be able to discern individuals whose disease is more progressive and requires more aggressive treatment.
About LymPro Test®
The Lymphocyte Proliferation Test (LymPro Test®) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes to withstand an external mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons. LymPro is unique in the use of peripheral blood lymphocytes (PBLs) as a surrogate for neuronal cell function, suggesting a common immune-based relationship between PBLs and neurons in the brain.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard™) that led to MANF's discovery.
For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
how about just bolding the might?? :)
Nice opinion...you know the saying!! Happy Mothers Day!
Perhaps an explanation from the enlightened one?? Do you even know what they do?
Have you ever seen another come off the greys that was a scam? Yea...didn't think so...
Good luck! Better than losing 83!
GTAT will be over a dollar within 3-9 months. The only bags we'll be holding will be gucci.... :)
Amarantus Forms Alzheimer's Disease Diagnostics Scientific Advisory Board http://ir.amarantus.com/company-news/detail/1914
The revenues are flowing in. Follow the money!!
And it drops 5% the second he buys!! LMAO
I'd imagine it's the short bus....
you say..."Why should a bunch of Gamblers make Profit on Other's Losses"???
Because that IS what makes a market.
the old shareholders have the same opportunity as the ones entering now.
Your thinking is not reality.
What happened to all the people who said triple zero's after the delisting??
The message is clear....this will trade on otcbb this year. possibly as early as Feb.
just keep looking....whatever happens don't stop.
Gap filled.....
Fortunately I don't invest on what others think...
The story is unfolding before our eyes...just sit back and relax.
I really don't feel the need to but thanks for the trading advice!
It's truly only my concern what I do with my money and should not be yours. But I hate to see you worry....
SAMP 840,000 0.0058 +346.15% 4870.20
Mine Too!!
Whats up with that??
Agreed...And with a whole new wealth of knowledge on legalties and logistics. The amount learned from failure with Apple could catipult GTAT to a whole new level. This is gonna be a growth story this year.
Interesting.
http://ih.advfn.com/p.php?pid=nmona&article=64966788&symbol=CANN
SUBJECT TO COMPLETION DATED JANUARY 2, 2015
PRELIMINARY PROSPECTUS
ADVANCED CANNABIS SOLUTIONS, INC.
Common Stock
By means of this prospectus a number of our shareholders are offering to sell up to 3,364,700 shares of our common stock which are issuable upon the exercise of outstanding warrants or the conversion of notes.
Our common stock trades under the symbol “CANN” on an unsolicited basis in the grey market. On December 31, 2014, the closing price of our common stock was $1.00.
Our common stock is presently not traded or reported on any market, securities exchange or quotation system. After the effective date of this prospectus, the selling security holders may offer the shares covered herein in negotiated transactions or otherwise at a fixed price of $4.40 per share and after quotation on a public market at market prices prevailing at the time, or at privately negotiated prices. The selling security holders will pay all brokerage commissions and discounts attributable to the sale of the shares, plus brokerage fees. The selling security holders will receive all of the net proceeds from the offering. We will bear all costs associated with the registration of the shares covered by this prospectus.
We have applied to seek quotation on the OTC Markets quotation system (“OTCQB”), but there is no guarantee that such quotation will be approved. Until our common stock is quoted on the OTCQB, selling security holders must sell their shares at the fixed price of $4.40 per share. In the event we are cleared by FINRA for quotation, selling security holders may use any one or more of the following methods when selling shares: (i) ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; (ii) block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; (iii) purchases by a broker-dealer as principal and resale by the broker-dealer for its account; (iv) an exchange distribution in accordance with the rules of the applicable exchange; (v) privately negotiated transactions; (vi) effected short sales after the date the registration statement of which this prospectus is a part is declared effective by the Securities and Exchange Commission (the “SEC”); (vii) through the writing or settlement of options or other hedging transactions, whether through options exchange or otherwise; (viii) broker-dealers may agree with the selling security holders to sell a specified number of such shares at a stipulated price per share; and (ix) a combination of any such methods of sale.
The fixed price of $4.40 per share is based on the conversion price of the notes and the exercise price of the warrants for which the underlying shares of common stock are registered herein. The $4.40 per share exercise and conversion price was negotiated at arms’ length and does not necessarily relate to any standard indicia of value such as earnings, asset value or otherwise.
Although we will receive proceeds if any of our warrants are exercised, we will not receive any proceeds from the sale of the common stock by the selling stockholders.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
JP Have you sold? You sure have changed your tune.
Funny how you would PM me telling me what a great investment is and to load the boat and then this.
Getting some action today!
Just wait till January!!
Because Apples market cap is over 600 BILLION dollars versus GTAT at 60 million. 1000 times more value. It's literally inconsequencial to their bottom line. They are MASSIVE.
Who Cares???
100 percent agree. Years of avoided litigation and headache that just wastes money time. This is phenominal and I wish I would of bought more.
Amarantus Appoints Elise Brownell, Ph.D., as Senior Vice President of Operations and Project Management
http://ir.amarantus.com/company-news/detail/1804
Great info Xena!! It's interesting the games being played here.
Just a matter of time!
This is the time to add folks!!! Shorty is desperate!!!!
The GTAT Group has been a diversified technology company producing
advanced materials and equipment for the global consumer electronics, power electronics, solar
and light-emitting diode (“LED”) industries for many years. Among other things, the GTAT
Group has more than 40 years of experience developing technological innovations in connection
with the manufacturing of furnaces to grow sapphire for industrial use. After diamonds, sapphire
is the second hardest substance on Earth. Sapphire is scratch-resistant and has other properties
that make it an ideal material for display applications where those properties provide significant
advantages over strengthened glass or other materials used in the consumer electronics field.
Sapphire can be fabricated into a variety of shapes and sizes for use in consumer electronics, as
well as the military, LED industries, and other industries. In the consumer electronics field,
sapphire is currently used in watch crystals, camera lenses, and smartphone displays. GTAT’s
customers in Asia, which have purchased from GTAT and operate nearly 500 sapphire furnaces
installed by GTAT, are significant suppliers to the consumer electronics market, where the
sapphire materials they make are used in a variety of applications, including the lens cover,
finger print sensor and cover glass for smartphones.
Most sapphire manufacturers using non-GTAT furnaces produce boules of less than
100kg in size.
In light of the inability to negotiate changes to the Apple Agreements necessary
for GTAT to operate profitably, GTAT reluctantly commenced these chapter 11 cases to
preserve the value of its business by separating itself from the business relationship with Apple.
Once GTAT has separated itself from the business relationship with Apple, GTAT believes that
the completion of its restructuring efforts will allow it to focus its resources on the operation of
its core business of selling sapphire furnaces and other products. Reorganized with an
appropriate capital structure, GTAT would emerge from chapter 11 in a stronger position and
with a sustainable business model that will allow it to compete effectively in the marketplace.